ImmunoGen Emerges from Genentech’s Shadow With Novel Cancer Drugs

Arlene Weintraub When ImmunoGen (NASDAQ: IMGN) said yesterday that it had started human trials of a new drug to treat ovarian cancer and other solid tumors, the announcement marked a coming out of s…
Read the full story: Xconomy Life Sciences